Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: J Vasc Surg. 2018 Feb 1;68(1):176–181.e1. doi: 10.1016/j.jvs.2017.09.057

Figure 1. Trial design of CHAMP.

Figure 1

After screening, patients are enrolled into either the cBMA or MSC arm of CHAMP. Subjects are randomized to one of four time points within 21 days of cell therapy administration. At that time, BKA is performed and tissue is harvested. All patients are followed for six months post-amputation.